Clinical Trial

A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA

Unknown Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 2, 2024 (before its estimated March 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Efficacy and safety of Romiplostim in the treatment of refractory transfusion-dependent NSAA.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06535685
Lead Sponsor Peking Union Medical College Hospital
Conditions Aplastic Anemia
Enrollment 40 participants
Start Date 2024-08-02
Primary Completion 2025-03-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-02